12.17
Intellia Therapeutics Inc stock is traded at $12.17, with a volume of 4.39M.
It is down -0.65% in the last 24 hours and up +22.43% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.25
Open:
$12.61
24h Volume:
4.39M
Relative Volume:
1.52
Market Cap:
$1.24B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.2208
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+13.74%
1M Performance:
+22.43%
6M Performance:
-48.45%
1Y Performance:
-54.72%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NTLA
Intellia Therapeutics Inc
|
12.17 | 1.24B | 45.97M | -508.80M | -382.65M | -5.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Apr-13-23 | Initiated | Canaccord Genuity | Buy |
Mar-21-23 | Initiated | Bernstein | Outperform |
Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Sep-01-22 | Initiated | Citigroup | Sell |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Jun-16-22 | Initiated | BofA Securities | Buy |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Feb-18-22 | Initiated | William Blair | Outperform |
Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-31-22 | Initiated | Cowen | Outperform |
Jan-07-22 | Initiated | Piper Sandler | Overweight |
Oct-05-21 | Initiated | Guggenheim | Buy |
Sep-24-21 | Initiated | Stifel | Buy |
Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
Jun-11-21 | Initiated | H.C. Wainwright | Buy |
May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
May-04-21 | Initiated | RBC Capital Mkts | Outperform |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-27-20 | Initiated | Truist | Buy |
Oct-14-20 | Initiated | Wells Fargo | Overweight |
Sep-18-20 | Initiated | Goldman | Buy |
Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jul-09-19 | Initiated | Robert W. Baird | Outperform |
Jun-10-19 | Initiated | ROTH Capital | Neutral |
May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
Oct-29-18 | Initiated | Credit Suisse | Neutral |
Sep-21-18 | Initiated | Raymond James | Mkt Perform |
May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
Nov-01-17 | Reiterated | Jefferies | Buy |
Jun-22-17 | Resumed | Jefferies | Buy |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure ... - The Bakersfield Californian
ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - GlobeNewswire Inc.
Intellia signs major lease for expansion, amends existing lease - Investing.com India
Intellia Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information - GlobeNewswire
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - PR Newswire
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar? - Yahoo Canada Finance
Intellia Therapeutics to Hold Conference Call to Discuss - GlobeNewswire
Gene Editing Pioneer Intellia Sets Critical Q4 Earnings Review: Will CRISPR Progress Match Expectations? - StockTitan
The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday - MarketBeat
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
Chevy Chase Trust Holdings LLC Sells 522,712 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - TradingView
Shareholders of Intellia Therapeutics, Inc. Should Contact - GlobeNewswire
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA - TradingView
How to Take Advantage of moves in (NTLA) - Stock Traders Daily
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Intellia - GlobeNewswire
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire
Intellia Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - Morningstar
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
2025-02-16 | INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics | NDAQ:NTLA | Press Release - Stockhouse Publishing
Sumitomo Mitsui Trust Group Inc. Sells 156,736 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages - GlobeNewswire
Intellia Therapeutics (NASDAQ:NTLA) Sets New 1-Year LowWhat's Next? - MarketBeat
INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently - Insider Monkey
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect? - Yahoo Finance
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders - PR Newswire
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowShould You Sell? - MarketBeat
Intellia Therapeutics, Inc. Shareholder Notice: Shareholder - GlobeNewswire
Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA - GlobeNewswire
Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Investor Alert: Robbins LLP Informs Stockholders of the Intellia Therapeutics, Inc. Class Action - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: - GlobeNewswire
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: Investors With Large Losses in - The Bakersfield Californian
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):